NEW YORK (GenomeWeb) – Several equity research today initiated coverage of Guardant Health with favorable ratings, citing the firm's strong liquid biopsy testing portfolio — and especially its Guardant360 assay — as reasons for their optimism.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?Login Now.
A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.
A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.
A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.